CEACAM5 and metastatic neoplasm: For the subset of patients with potentially resectable metastatic disease and detectable mutations by the SCODA assay in pre-operative plasma, we further analyzed post-operative plasma samples obtained on the fifth post-operative day and at routine follow-up visits in the context of CEA levels, cross-sectional imaging, and post-operative therapy.